middle.news
How Will Radiopharm’s RAD101 Transform Brain Metastases Diagnosis?
8:37am on Wednesday 11th of June, 2025 AEST
•
Healthcare
Read Story
How Will Radiopharm’s RAD101 Transform Brain Metastases Diagnosis?
8:37am on Wednesday 11th of June, 2025 AEST
Key Points
FDA grants Fast Track designation to RAD101 for brain metastases imaging
RAD101 targets fatty acid synthase to differentiate tumor recurrence from treatment effects
Phase 2 trial underway in the U.S. with topline results expected in late 2025
Positive Phase 2a data from Imperial College of London supports RAD101’s diagnostic potential
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Radiopharm Theranostics (ASX:RAD)
OPEN ARTICLE